Testosterone Science

Media Watch

Hims expands testosterone care with injectable and oral TRT, its largest men’s health launch to date

Specific claim evaluated

An estimated 20 million men in the US are affected by low testosterone, citing a 2006 study.

Primary research supporting or contradicting the claim

The 2006 study found a 38.7% prevalence of total testosterone below 300 ng/dL in men aged 45 or older attending primary care, without requiring symptoms (Mulligan et al., 2006). In a community sample, symptomatic androgen deficiency affected 5.6% of men aged 30 to 79 years (Araujo et al., 2007).

Corrected evidence-based interpretation

A primary care biochemical prevalence cannot be projected onto the US male population. The number of men with symptomatic hypogonadism is substantially lower.

Rationale for grade

The release extrapolates a biochemical prevalence from a primary care sample to the national population and presents it as the number of men affected. It also describes enclomiphene as shown to double testosterone, citing an infertility study, and gives no safety information.

References

  1. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-4247. PMID
    Supporting excerpt: "Crude prevalence of symptomatic androgen deficiency was 5.6%"
  2. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-769. PMID
    Supporting excerpt: "in men aged > or = 45 years presenting to primary care offices"

Post a Comment

Shared decision making

Bring the evidence to your next consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.